绿康生化股份有限公司 2025 年第三季度报告 证券代码：002868 证券简称：*ST 绿康 公告编号：2025-107 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 绿康生化股份有限公司 2025 年第三季度报告 1 绿康生化股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 115,800,351.16 | -20.45% | ...

Core Viewpoint - The animal health sector experienced a decline of 0.36% on October 22, with Dayu Biological leading the drop. The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1]. Stock Performance Summary - The following stocks in the animal health sector showed varied performance: - Shengwu Co. (600201) closed at 10.78, up 0.56% with a trading volume of 327,000 shares and a turnover of 351 million yuan - Ruipu Biological (300119) closed at 21.50, up 0.51% with a trading volume of 73,200 shares and a turnover of 158 million yuan - Haili Biological (603718) closed at 7.04, up 0.28% with a trading volume of 44,200 shares and a turnover of 31.17 million yuan - Dayu Biological (920970) closed at 9.46, down 1.25% with a trading volume of 20,800 shares and a turnover of 19.89 million yuan - ST Lvkang (002868) closed at 28.49, down 1.18% with a trading volume of 9,904 shares and a turnover of 28.26 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 47.45 million yuan from institutional investors, while retail investors contributed a net inflow of 36.66 million yuan. Speculative funds recorded a net inflow of 10.80 million yuan [2][3]. - Specific stock capital flows included: - Shunlian Biological (688098) had a net inflow of 6.94 million yuan from institutional investors but a net outflow of 12.58 million yuan from retail investors - Ruipu Biological (300119) experienced a net outflow of 2.94 million yuan from institutional investors, with a significant net inflow of 13.74 million yuan from speculative funds [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.02% on October 21, with Bioworks leading the drop. Meanwhile, the Shanghai Composite Index rose by 1.36% and the Shenzhen Component Index increased by 2.06% [1]. Group 1: Market Performance - The animal health sector's performance was mixed, with individual stocks showing varying degrees of increase and decrease. Notably, the top gainers included: - Driving Force (4.50% increase) [1] - Dayu Biological (3.46% increase) [1] - Yongshun Biological (2.06% increase) [1] - Conversely, Bioworks saw a decline of 2.10%, leading the losses in the sector [2]. Group 2: Trading Volume and Capital Flow - The trading volume for the animal health sector indicated a net outflow of 151 million yuan from institutional investors, while retail investors saw a net inflow of 116 million yuan [2]. - The capital flow for individual stocks showed significant movements, with: - Key stock, Bioworks, experiencing a net outflow of 6.46 million yuan from institutional investors [3]. - Retail investors contributed a net inflow of 7.59 million yuan to Zhongmu Co. [3]. Group 3: Individual Stock Analysis - The following stocks had notable capital flows: - KQ Biological had a net inflow of 1.83 million yuan from institutional investors [3]. - ST Green Health faced a net outflow of 4.37 million yuan from institutional investors [3]. - The stock of Rui Pu Biological saw a net inflow of 17.22 million yuan from retail investors despite a net outflow from institutional investors [3].

关于控股股东、股东协议转让股份暨 控制权拟发生变更的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：002868 证券简称：*ST 绿康 公告编号：2025-104 绿康生化股份有限公司 1、2025 年 10 月 20 日，上海康怡投资有限公司（以下简称"康怡投资"）、 杭州义睿投资合伙企业（有限合伙）（以下简称"义睿投资"）、上饶市长鑫贰 号企业管理中心（有限合伙）（以下简称"长鑫贰号"）、杭州皓赢投资合伙企 业（有限合伙）（以下简称"皓赢投资"）与福建纵腾网络有限公司（以下简称 "纵腾网络"）分别出具了《关于股份转让协议延期的确认函（二）》，同意延 长《股份转让协议》第 13.2.3 条约定的截止日至 2025 年 12 月 31 日（即 2025 年 4 月 24 日起二百五十一（251）个自然日），即在 2025 年 12 月 31 日前，不 会根据《股份转让协议》第 13.2.3 条的约定要求解除《股份转让协议》。 2、本次股份转让在实际交割前，须取得深圳证券交易所对本次股份转让出 具的确认意见书，以及经中国证券登记 ...

Market Overview - The animal health sector increased by 0.81% on October 20, with Xianfeng Holdings leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Xianfeng Holdings (002141) closed at 4.06, up 5.45% with a trading volume of 588,700 shares and a turnover of 237 million yuan [1] - Other notable stocks included ST Lvkang (002868) at 28.36, up 5.00%, and Biological Shares (600201) at 10.95, up 1.48% [1] - The overall trading volume and turnover for the animal health sector were significant, indicating active market participation [1] Capital Flow - The animal health sector saw a net inflow of 31.5863 million yuan from institutional investors, while retail investors experienced a net outflow of 10.9434 million yuan [2] - The main capital inflow was primarily directed towards Xianfeng Holdings, which had a net inflow of 28.5381 million yuan [3] - Conversely, stocks like Shunlian Biological (688088) and ST Lvkang experienced net outflows from retail investors, indicating a shift in investor sentiment [3]

Core Insights - The animal health sector experienced a decline of 0.28% on October 17, with Ruipu Biotech leading the drop [1][2] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Shenyuan Biological (688088) saw a significant increase of 10.65%, closing at 11.43 with a trading volume of 319,600 shares and a turnover of 368 million yuan [1] - Other notable gainers included Yongshun Biological (920729) with a rise of 2.94% and Xianfeng Holdings (002141) with an increase of 1.85% [1] - Conversely, Ruipu Biotech (300119) fell by 2.47%, closing at 21.69 with a trading volume of 109,100 shares and a turnover of 239 million yuan [2] Capital Flow - The animal health sector saw a net inflow of 33.17 million yuan from institutional investors, while retail investors experienced a net outflow of 37.18 million yuan [2][3] - Shenyuan Biological had a net inflow of 76.52 million yuan from institutional investors, representing 20.82% of its trading volume [3] - In contrast, other companies like XD Plai Ke (603566) and Huayi Biological (603718) faced significant net outflows from both institutional and retail investors [3]

Core Viewpoint - The animal health sector experienced a decline of 0.85% on October 16, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.1%, while the Shenzhen Component Index fell by 0.25 [1]. Group 1: Market Performance - The closing price of *ST Lvkang was 27.48, with an increase of 5.01%, while other stocks in the sector showed mixed results [1]. - The total trading volume for the animal health sector was significant, with *ST Lvkang recording a volume of 14,900 hands and a transaction amount of 40.81 million yuan [1]. - The overall market saw a net outflow of 126 million yuan from the animal health sector, with retail investors contributing a net inflow of 91.62 million yuan [2]. Group 2: Individual Stock Analysis - *ST Lvkang had a net inflow of 5.23 million yuan from major funds, while Xianfeng Holdings saw a net outflow of 3.36 million yuan [3]. - The stock of RuiPu Bio had a significant net outflow of 25.44 million yuan from major funds, despite a retail net inflow of 39.62 million yuan [3]. - The stock of HaiLi Bio experienced a net outflow of 4.47 million yuan from major funds, with a retail net inflow of 2.64 million yuan [3].

Core Insights - The animal health sector experienced a 1.5% increase on October 15, with Bio-Pharmaceuticals leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Bio-Pharmaceuticals (600201) closed at 11.03, up 4.06% with a trading volume of 563,500 shares and a turnover of 614 million yuan [1] - Other notable stocks include: - Shunlian Bio (688098) at 10.48, up 2.95% [1] - Ruipu Bio (300119) at 22.56, up 2.31% [1] - Yongshun Bio (920729) at 676, up 1.93% [1] - Dayu Bio (920970) at 9.45, up 1.61% [1] Capital Flow - The animal health sector saw a net outflow of 5.71 million yuan from institutional investors, while retail investors contributed a net inflow of 1.83 million yuan [2] - The capital flow for key stocks includes: - Ruipu Bio had a net inflow of 25.55 million yuan from institutional investors [3] - Hai Li Bio experienced a net outflow of 3.22 million yuan from institutional investors [3] - KQ Bio (688526) had a net inflow of 5.26 million yuan from retail investors [3]

Core Viewpoint - The animal health sector experienced a decline of 0.68% on October 14, with Xianfeng Holdings leading the drop. The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1]. Stock Performance Summary - Zhongmu Co., Ltd. (600195) closed at 7.35, up 1.66% with a trading volume of 120,000 shares and a transaction value of 87.91 million yuan [1]. - Yongshun Biological (920729) closed at 9.31, up 0.54% with a trading volume of 13,800 shares and a transaction value of 12.82 million yuan [1]. - Biological Co. (600201) closed at 10.60, up 0.28% with a trading volume of 624,200 shares and a transaction value of 672 million yuan [1]. - Other notable stocks include Ruip Bio (300119) down 0.45% and Jinhai Bio (002688) down 0.98% [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 8.12 million yuan from institutional investors, while retail investors had a net inflow of 4.61 million yuan [2][3]. - Major stocks like Biological Co. (600201) experienced a net inflow of 62.91 million yuan from institutional investors, while Xianfeng Holdings (002141) saw a net outflow of 9.04 million yuan [3].

绿康生化股份有限公司 关于公司独立董事辞职的公告 证券代码：002868 证券简称：*ST 绿康 公告编号：2025-103 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）董事会于 2025 年 10 月 11 日收到公司独立董事王双女士的辞职报告。王双女士因个人身体原因及本职工作 事务繁忙，已难以继续全面、有效地履行独立董事职责。申请辞去公司第五届董事会独 立董事以及在相关专门委员会所任委员职务，辞职后王双女士不再担任公司及其控股子 公司的任何职务。 根据《上市公司独立董事管理办法》等相关法律法规及《公司章程》的规定，王双 女士的辞职，将导致公司独立董事占董事会成员的比例低于三分之一，王双女士的辞职 申请将在公司股东会选举产生新的独立董事后生效。在此期间，王双女士仍将按照相关 法律、法规和《公司章程》的规定继续履行其作为公司独立董事及相关专门委员会委员 的相关职责。公司董事会将按照相关规定，尽快完成独立董事补选工作。 公司及董事会对王双女士在其任职期间为公司所做出的贡献表示衷心的感谢！ 特此公告。 截至 ...